—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

A phase 2 trial evaluated the efficacy of nivolumab added to brachytherapy, external beam radiation therapy, and ADT in men with high-risk grade group 5 prostate cancer.

About 12% of prostate cancer patients receiving androgen deprivation therapy underwent all recommended screening for treatment-related adverse events. Many prostate cancer patients receiving androgen ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

WASHINGTON — Combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improves disease-free survival in men with intermediate-risk prostate cancer compared with high-dose ...

Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...